​

Novartis (NVS) Stock Forecast, Price Target & Predictions

OverviewOwnershipChartTranscripts

NVS Stock Forecast

Novartis (NVS) stock forecast, based on 25 Wall Street analysts, predicts a 12-month average price target of $127.00, with a high of $143.00 and a low of $112.00. This represents a -4.04% decline from the last price of $132.35.

$95 $105 $115 $125 $135 $145 High: $143 Avg: $127 Low: $112 Last Closed Price: $132.35

NVS Stock Rating

Novartis stock's rating consensus is Hold, based on 25 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (20.00%), 18 Hold (72.00%), 2 Sell (8.00%), and 0 Strong Sell (0.00%).

Hold
Total 25 0 2 18 5 Strong Sell Sell Hold Buy Strong Buy

NVS Price Target Upside V Benchmarks

TypeNameUpside
StockNovartis-4.04%
SectorHealthcare Stocks 15.45%
IndustryDrug Manufacturers - General Stocks7.11%

Price Target Trends

1M3M12M
# Anlaysts233
Avg Price Target$127.50$127.00$127.00
Last Closing Price$132.35$132.35$132.35
Upside/Downside-3.66%-4.04%-4.04%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Dec, 251172-11
Nov, 251-82-11
Oct, 251-72111
Sep, 252-81112
Aug, 252-72112
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 10, 2025HSBC$112.00$131.01-14.51%-15.38%
Dec 03, 2025Morgan Stanley$143.00$132.288.10%8.05%
Oct 29, 2025Wan NurhayatiCFRA$126.00$123.332.16%-4.80%
Oct 30, 2024Etzer DaroutBMO Capital$120.00$109.919.18%-9.33%
Sep 05, 2024James QuigleyGoldman Sachs$121.00$119.381.36%-8.58%
Jul 19, 2024Etzer DaroutBMO Capital$118.00$106.1311.18%-10.84%
Apr 23, 2024Wan NurhayatiCFRA$108.00$97.2711.03%-18.40%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 10, 2025HSBCReduceReducehold
Dec 03, 2025Morgan StanleyOverweightOverweighthold
Nov 25, 2025Bank of America SecuritiesBuyupgrade
Nov 10, 2025Cowen & Co.HoldHoldhold
Oct 31, 2025Morgan StanleyEqual-WeightOverweightupgrade
Oct 29, 2025CFRAHoldHoldhold
Oct 27, 2025H.C. WainwrightNeutraldowngrade
Sep 12, 2025Goldman SachsNeutralSelldowngrade
Aug 21, 2025Deutsche BankBuyBuyhold
Feb 04, 2025Deutsche BankHoldBuyupgrade

Financial Forecast

EPS Forecast

$3 $4 $5 $6 $7 $8 $9 $10 $11 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.55$10.71$3.19------
Avg Forecast$5.49$5.96$5.70$6.67$7.54$8.13$8.51$9.01$9.67
High Forecast$5.67$6.15$5.89$6.82$7.62$8.46$8.81$9.33$10.02
Low Forecast$5.32$5.77$5.55$6.55$7.50$8.04$8.29$8.78$9.43
Surprise %-35.34%79.70%-44.04%------

Revenue Forecast

$40B $44B $48B $52B $56B $60B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$49.90B$52.88B$51.83B$46.66B-----
Avg Forecast$49.25B$52.09B$51.52B$46.80B$50.44B$52.03B$53.14B$54.63B$55.82B
High Forecast$50.47B$53.38B$52.85B$53.04B$51.18B$52.60B$54.61B$56.14B$57.36B
Low Forecast$48.05B$50.82B$50.45B$43.97B$50.04B$51.47B$52.10B$53.56B$54.72B
Surprise %1.32%1.51%0.60%-0.30%-----

Net Income Forecast

$5B $11B $17B $23B $29B $35B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$8.07B$24.02B$6.96B$14.85B-----
Avg Forecast$7.64B$24.24B$25.22B$27.74B$15.77B$17.02B$17.79B$18.85B$20.24B
High Forecast$9.16B$29.08B$30.26B$33.29B$15.94B$17.69B$18.43B$19.52B$20.97B
Low Forecast$6.11B$19.39B$20.18B$22.19B$15.69B$16.81B$17.34B$18.37B$19.72B
Surprise %5.71%-0.89%-72.42%-46.47%-----

NVS Forecast FAQ

Is Novartis stock a buy?

Novartis stock has a consensus rating of Hold, based on 25 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 18 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that Novartis is a neutral investment for most analysts.

What is Novartis's price target?

Novartis's price target, set by 25 Wall Street analysts, averages $127 over the next 12 months. The price target range spans from $112 at the low end to $143 at the high end, suggesting a potential -4.04% change from the previous closing price of $132.35.

How does Novartis stock forecast compare to its benchmarks?

Novartis's stock forecast shows a -4.04% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the drug manufacturers - general stocks industry (7.11%).

What is the breakdown of analyst ratings for Novartis over the past three months?

  • December 2025: 9.09% Strong Buy, 9.09% Buy, 63.64% Hold, 18.18% Sell, 0% Strong Sell.
  • November 2025: 9.09% Strong Buy, 0% Buy, 72.73% Hold, 18.18% Sell, 0% Strong Sell.
  • October 2025: 9.09% Strong Buy, 0% Buy, 63.64% Hold, 18.18% Sell, 9.09% Strong Sell.

What is Novartis’s EPS forecast?

Novartis's average annual EPS forecast for its fiscal year ending in December 2024 is $7.54, marking a 0% decrease from the reported $0 in 2023. Estimates for the following years are $8.13 in 2025, $8.51 in 2026, $9.01 in 2027, and $9.67 in 2028.

What is Novartis’s revenue forecast?

Novartis's average annual revenue forecast for its fiscal year ending in December 2024 is $50.44B, reflecting a 8.09% increase from the reported $46.66B in 2023. The forecast for 2025 is $52.03B, followed by $53.14B for 2026, $54.63B for 2027, and $55.82B for 2028.

What is Novartis’s net income forecast?

Novartis's net income forecast for the fiscal year ending in December 2024 stands at $15.77B, representing an 6.20% increase from the reported $14.85B in 2023. Projections indicate $17.02B in 2025, $17.79B in 2026, $18.85B in 2027, and $20.24B in 2028.